Extensive expansion at Lonza’s Tampa site provides streamlined services for solid oral dosage forms

Lonza announced the completion of a $15M multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity at its Tampa, FL (USA) site. The expansion will enable the Tampa site to provide more integrated services for customers across early-stage product development, clinical trial material manufacture and commercialization of innovative drug products. The Tampa site is part of Lonza’s global network for the design, development and manufacturing of drug substances and intermediates, particle engineering / bioavailability enhancement and drug products for oral and inhaled applications.

As part of the multi-year investment, the site now boasts a new fully equipped Product Development & QC Laboratory area with 13 processing suites and two new packaging suites that can support commercial packaging, including low-humidity environments and serialization for complete tracking and tracing of commercial products. Lonza also added new manufacturing suites and dedicated sampling and dispensing areas capable of handling highly potent compounds.

In addition, Lonza expanded and renovated the cGMP Manufacturing Cleanroom facility, as well as completely renovating 25,000 sq ft of the existing cGMP OSD Manufacturing Cleanroom Facility.

The expansion included encapsulation and micro-dosing capabilities for Xcelodose Precision Powder Micro-Dosing Technology, Glatt GPCG-10 fluid bed processing and Harro Hoefliger Modu-C capsule filling.